MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/15266028241304303

Медицинская библиотека · Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists · 2024

Long-term Outcomes of the AcoArt II-BTK Trial: Drug-Coated Balloon Angioplasty Compared With Uncoated Balloons for the Treatment of Infrapopliteal Artery Lesions.

Sun Guoyi, Liu Jie, Jia Xin, Xiong Jiang, Ma Xiaohui, Zhang Hongpeng, Guo Wei

СтатьяМногоцентровое исследованиеРандомизированное исследованиеСравнительное исследованиеПеревод в очереди

Аннотация

PURPOSE: Previous studies have indicated mixed short-term outcomes between drug-coated balloon (DCB) angioplasty and percutaneous transluminal angioplasty (PTA) in the treatment of infrapopliteal lesions. However, the long-term durability of DCB angioplasty remains uncertain. The objective of this study is to present the long-term outcomes of DCB angioplasty for infrapopliteal lesions in patients with critical limb ischemia (CLI).

MATERIALS AND

METHODS

The AcoArt II-BTK Trial was a prospective, multicenter, randomized, single-blinded trial that enrolled 120 patients with CLI. The patients were randomized 1:1 to DCB angioplasty or PTA. Assessments over 5 years included freedom from all-cause death, freedom from clinically driven target lesion revascularization, and occurrence of major amputation. Additional endpoints included the rate of composite major adverse events.

RESULTS

Over 5 years, patients treated with DCB angioplasty demonstrated a higher rate of freedom from all-cause death than patients treated with PTA (Kaplan-Meier estimate 74.6% vs 57.2%; log-rank p=0.04). The major amputation rate was 5.2% for DCB angioplasty compared with 1.8% for PTA (log-rank p=0.347). Freedom from clinically driven target lesion revascularization was 70.5% and 53.7%, respectively (log-rank p=0.058). The rate of composite major adverse events was 34.5% for DCB angioplasty and 56.1% for PTA (log-rank p=0.013), and this statistically significant difference persisted throughout the 5-year follow-up period.

CONCLUSION

Infrapopliteal artery revascularization in patients with CLI using Litos/Tulip DCB angioplasty showed superior 5-year overall survival compared with PTA. The DCB angioplasty group had a consistently lower rate of major adverse events within 5 years of follow-up.Clinical ImpactThe use of DCB in infrapopliteal arterial lesions has been controversial regarding both early and mid-term outcomes, with limited data on long-term results. However, this article demonstrates that the Litos/Tulip DCB exhibits favorable long-term outcomes in infrapopliteal artery lesions. These positive findings provide robust evidence supporting the use of DCB in treating infrapopliteal artery disease.

Для цитирования: Sun Guoyi, Liu Jie, Jia Xin, Xiong Jiang, Ma Xiaohui, Zhang Hongpeng, Guo Wei. Long-term Outcomes of the AcoArt II-BTK Trial: Drug-Coated Balloon Angioplasty Compared With Uncoated Balloons for the Treatment of Infrapopliteal Artery Lesions.. Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists. 2024. DOI: 10.1177/15266028241304303.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.